menu search

Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting

Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting
Posters will feature preliminary Phase 1b combination data for potential best-in-class ERK1/2 inhibitor ERAS-007 with encorafenib and cetuximab or with palbociclib in patients with GI malignancies SAN DIEGO, April 26, 2023 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK […] The post Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Me... Read More
Posted: Apr 26 2023, 21:00
Author Name: forextv
Views: 081966

Search within

Pages Search Results: